| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/24/2010 | US7781435 (S)-2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid {1-[2-(3-ethoxy-propylamino) -ethyl]-1H-imidazol-4-yl}-amide, having beta-amyloid peptide production inhibitory activity, used for the treatment of neurodegenerative disorders such as Alzheimer's disease |
| 08/24/2010 | US7781434 7-Chloro-2-isopropyl-5-[3-(morpholine-4-carbonyl)-isoxazol-5-yl]-2,3-dihydro-isoindol-1-one; drug targets in the therapy of acute and chronic neurological and psychiatric disorders and chronic and acute pain disorders; schizophrenia or anxiety; Sandmeyer reaction of a 4-bromoaniline |
| 08/24/2010 | US7781433 Pharmaceutical compounds |
| 08/24/2010 | US7781432 analgesic. especially acute, chronic and/or neuropathic pain; epilepsy and other CNS-related disorders as well as for neuroprotection or cardioprotection; 9-benzyl-8-(cyclopentylamine)-6-(4-nitrobenzyl-mercaptopurine |
| 08/24/2010 | US7781431 Thienopyrroles as antiviral agents |
| 08/24/2010 | US7781430 Benzoxazole carboxamides for treating CINV and IBS-D |
| 08/24/2010 | US7781429 solubilizing a nonsteroidal antiinflammatory drug (NSAID) such as diclofenac by combining with at least two of camphor, menthol and thymol |
| 08/24/2010 | US7781428 Pyrazoline compounds |
| 08/24/2010 | US7781427 cyclization of a 1,4-benzodiazepine with cyclopentene. in a diels-alders reaction to give a decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline, then resolving to form diastereomeric salts and dimer impurities; neuroleptic and dietetic agents |
| 08/24/2010 | US7781426 cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis |
| 08/24/2010 | US7781423 administering to a cancer patients, heterocyclic trialkyl ammonium-compounds such as [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride, to normalize blood cell and platelet counts and to reduce side effects of radiotherapy and chemotherapy |
| 08/24/2010 | US7781422 Macrocyclic indole compounds, e.g., 16-cyclohexyl-3,6-dimethyl-17-phenyl-4,5,6,7,8,9-hexahydro-1H-13,15-(ethanediylidene)pyrrolo[2,1-f][1,2,7,10,13]thiatetraazacyclohexadecine-2,12(3H)-dione 10,10-dioxide; hepatitis C virus polymerase inhibitors |
| 08/24/2010 | US7781421 such as (3 alpha ,5 alpha )-21-bromo-3-hydroxy-18,21-cyclopregn-18(21)-en-20-one used as anesthetics, anticonvulsants, anxiolytic agents or for prophylaxis of sleep disorders or drug abuse and dependence |
| 08/24/2010 | US7781420 Use of clodronic acid for treatment podotrochlosis |
| 08/24/2010 | US7781419 bisphosphonate is etidronate, tiludronate, risedronate, zoledronic acid; dosing schedule in a stepped-up dosage amount that is at least one and a half times the recommended dose for osteoporosis |
| 08/24/2010 | US7781418 enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid; osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis; enhanced inhibitory effect on farnesyl pyrophosphate synthase |
| 08/24/2010 | US7781417 Cyclodextrin dimers and derivatives thereof, methods for preparing them and their use, in particular, for the solubilizing pharmacologically active substances |
| 08/24/2010 | US7781416 Inhibiting FGF growth factor with heparins; antitumor agents; angiogenesis inhibitor; antidiabetic agent treating diabetic retinopathy; antiinflammatory agent; treating retrolenticular fibroplasia, psoriasis, restenosis after angioplasty and after coronary by-pass; chemical intermediates; drug delivery |
| 08/24/2010 | US7781414 Targets for tumor growth inhibition |
| 08/24/2010 | US7781413 Comprises semaphorin polypeptide (SEMA3B) as tumor suppressor |
| 08/24/2010 | US7781412 triclosan, hexachlorophene, or dichlorophen and anthracyclines (adriamycin, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin); synergistic; reducing cardiotoxicity anticarcinogenic anthracycline drugs; inhibiting enzyme(s) that catalyze conversion to anthracycline metabolites |
| 08/24/2010 | US7781411 Derivatives of avermectin, avermectin monosaccharide and avermectin aglycone |
| 08/24/2010 | US7781410 treating acne or reducing the appearance of oil or pores on the skin, hair and scalp, comprising topical administration of 2'-hydroxy-2,3,5'-trimethoxychalcone, and optionally salicylic acid or benzoyl peroxide and a catechin |
| 08/24/2010 | US7781409 Composition for external use |
| 08/24/2010 | US7781408 Oral administration of gangliosides including 50% ganglioside GD3 as anticholesterol and antiinflammatory agents; decreased intestinal absorption of cholesterol; mediating inflammation of the intestine, retina or neural tissues; liquid or food suppliment for infants |
| 08/24/2010 | US7781407 Reacting a gluconic acid with lactic acid in the presence of calcium hydroxide and water to obtain a calcium gluconolactate molecule having the formula HO-CH2-(CHOH)4-COO-Ca-OOC-CH(-OH)-CH3 with molecular weight of 324.2994; physical and chemical properties; nutraceuticals |
| 08/24/2010 | US7781406 Modulating a transplantation-associated immune response for acute and chronic graft versus host disease (GVHD); kidney, heart and liver allogeneic transplantation; side effect reduction; biodrugs |
| 08/24/2010 | US7781394 Methods for identifying anti-tumor and/or anti-angiogenesis drugs with deoxynucleoside 5′-monophosphate N-glycosidase as the target |
| 08/24/2010 | US7781393 Methods for inhibiting tumor cell growth |
| 08/24/2010 | US7781188 Nucleotide and protein sequences of Nogo genes and methods based thereon |
| 08/24/2010 | US7781161 Detection cancer; controlling gene expression; detection hybrids |
| 08/24/2010 | US7780988 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| 08/24/2010 | US7780987 Coating comprising aqueous dispersion of neutral ester copolymer without functional groups, polyglycol having melting point greater than 55 degrees C, pharmaceutically acceptable excipients, coated onto pharmaceutical oral dosage form, cured; FDA Orange book listed patent for metformin HCl |
| 08/24/2010 | US7780986 Method of preparing sustained-release preparations of quinolone antibiotics |
| 08/24/2010 | US7780984 Methods and compositions for treating proliferative diseases |
| 08/24/2010 | US7780983 Amphoteric liposomes |
| 08/24/2010 | US7780978 Oral pharmaceutical compositions and methods of using the same |
| 08/24/2010 | US7780976 flat strip of supporting material, such as filter paper, having marked reference locations on each of one or more legs, for delivering controlled quantities of agents to the adnexa of the eye simultaneously upon dispensing liquid to strip at appropriate reference location |
| 08/24/2010 | US7780959 Feline granulocyte macrophage colony stimulating factor nucleic acid molecules |
| 08/24/2010 | US7780958 A biocompatible crosslinking polymer comprising acrylamide and methylene bis-acrylamide; medical procedure involves injection of polyacrylamide gel under the mucous membrane |
| 08/24/2010 | US7780957 Polyethylene glycol/polycation block copolymers |
| 08/24/2010 | US7780954 Glow and sunless tanning color enhancement by cationic copolymers |
| 08/24/2010 | US7779715 Shifter with actuator incorporating magnetic unlock mechanism |
| 08/24/2010 | CA2632585C Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene and processes for preparing said compound |
| 08/24/2010 | CA2621323C Histamine-3 receptor antagonists |
| 08/24/2010 | CA2611638C Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative |
| 08/24/2010 | CA2593621C Naphthalene derivatives, process for their preparation and pharmaceutical compositions containing them |
| 08/24/2010 | CA2593618C Naphthalene derivatives, process for their preparation and pharmaceutical compositions containing them |
| 08/24/2010 | CA2582049C Bilayer tablet comprising telmisartan and amlodipine |
| 08/24/2010 | CA2572897C Pharmaceutical composition for the treatment of bone fracture |
| 08/24/2010 | CA2570805C 2-(1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence |
| 08/24/2010 | CA2557368C Polynucleotide participating in rheumatoid arthritis and utilization of the same |
| 08/24/2010 | CA2551182C Novel kappa receptor selective opioid peptides |
| 08/24/2010 | CA2541066C Derivatives of indanyl-piperazines, the process for preparing them and the pharmaceutical compounds that contain them |
| 08/24/2010 | CA2536206C Pharmaceutical products comprising bisphosphonates |
| 08/24/2010 | CA2524377C Thiadiazine derivatives and use thereof as positive ampa receptor modulators |
| 08/24/2010 | CA2520897C Pyrrolo (2,1-c)(1,4) benzodiazepine dimers as antitumour agents and process thereof |
| 08/24/2010 | CA2511219C Cyclopentenone derivatives for cancer therapy |
| 08/24/2010 | CA2499314C Indole derivatives as beta-2 agonists |
| 08/24/2010 | CA2490907C Amide derivative |
| 08/24/2010 | CA2474031C Heterocyclic tripeptides as hepatitis c inhibitors |
| 08/24/2010 | CA2467857C Piperidine-based mch antagonists for treatment of obesity and cns disorders |
| 08/24/2010 | CA2467538C New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
| 08/24/2010 | CA2464906C Improved endoprosthetic device |
| 08/24/2010 | CA2463072C Thioester-terminated water soluble polymers and method of modifying the n-terminus of a polypeptide therewith |
| 08/24/2010 | CA2462510C Wipe formulation |
| 08/24/2010 | CA2460135C Use of pyridazinone compounds as phosphodiesterase iv inhibitors for treating cancer and other diseases |
| 08/24/2010 | CA2458468C Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma |
| 08/24/2010 | CA2445940C Prevention of epithelial cancer |
| 08/24/2010 | CA2445386C Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same |
| 08/24/2010 | CA2436808C Liquid antimicrobial compositions |
| 08/24/2010 | CA2430123C Agent for promoting excretion of accumulative chlorine-containing compound |
| 08/24/2010 | CA2430122C Antiobesity agent and health food |
| 08/24/2010 | CA2427520C Hydrophilic polymer blends used for dry cow therapy |
| 08/24/2010 | CA2426883C Methylphenidate modified release formulations |
| 08/24/2010 | CA2423103C N-acylsulfonamide apoptosis promoters |
| 08/24/2010 | CA2414583C Neuroprotective 7-beta-hydroxysteroids |
| 08/24/2010 | CA2391915C 3-phenyl-3,7-diazabicyclo[3.3.1]nonane compounds, process for their preparation and medicaments containing these compounds |
| 08/24/2010 | CA2385655C Dna immunization against chlamydia infection |
| 08/24/2010 | CA2362757C Effervescent pharmaceutical formulation containing metamizole |
| 08/24/2010 | CA2345445C A composition for the prevention and/or treatment of atherosclerosis |
| 08/24/2010 | CA2334858C Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression |
| 08/24/2010 | CA2302226C Camptothecin analogs and methods of preparation thereof |
| 08/24/2010 | CA2274985C Synthetic antisense oligodeoxynucleotides targeted to human acetylcholinesterase |
| 08/24/2010 | CA2273821C Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease |
| 08/24/2010 | CA2257393C Compositions and methods for reducing respiratory depression |
| 08/24/2010 | CA2256947C Depigmentation composition for lightening the skin and treating skin blotches. |
| 08/24/2010 | CA2201396C Multifunctional molecular complexes for gene transfer to cells |
| 08/24/2010 | CA2181924C Diagnosis and treatment of infections due to streptococci and enterococci |
| 08/20/2010 | CA2655893A1 Use of voacamine and related compounds to enhance the activity of existing malaria treatments |
| 08/20/2010 | CA2654839A1 Use of enoxaparin for reducing the risk of death in acutely ill medical patients |
| 08/19/2010 | WO2010094040A1 Template-independent ligation of single-stranded dna |
| 08/19/2010 | WO2010094009A2 Methods and compositions for the treatment of ras associated disorders |
| 08/19/2010 | WO2010093992A1 Anti-fungal formulation |
| 08/19/2010 | WO2010093930A1 Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| 08/19/2010 | WO2010093910A1 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione |
| 08/19/2010 | WO2010093890A2 Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) |
| 08/19/2010 | WO2010093889A2 Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide |
| 08/19/2010 | WO2010093885A1 Inhibitors of akt activity |
| 08/19/2010 | WO2010093873A2 Drug delivery through hydrogel plugs |